


FORM PTO-1449 (modified)  
To: U.S. Department of Commerce  
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT



Page 1 of 2

Attorney Docket No.

Client Ref.

053529-5007-01

Applicant: Berkley LYNCH *et al.*

Appln. No.: 10/725,189

Filing Date: December 2, 2003

Examiner: Unassigned

Group Art Unit: 1711

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
CyW	AR 20030009024 A1	01/09/2003	Curtis			
CyW	BR 20020142383 A1	10/03/2002	Merkulov <i>et al.</i>			
	CR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name			Ready Available	
						Enclosed	No	Enclosed	No
	DR								
	ER								
	FR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

CyW	GR	Bajjalieh SM, <i>et al.</i> SV2, a brain synaptic vesicle protein homologous to bacterial transporters. Science 1992; 257(5074):1271-1273				
	HR	Bajjalieh SM, <i>et al.</i> Brain contains two forms of synaptic vesicle protein 2. Proc Natl Acad Sci (USA). 1993; 90(6):2150-2154				
	IR	Bajjalieh SM, <i>et al.</i> Differential expression of synaptic vesicle protein 2 (SV2) isoforms. J Neurosci. 1994; 14(9):5223-5235				
	JR	Buckley, K <i>et al.</i> Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells. J Cell Biol. 1985; 100(4):1284-1294				
	KR	Crowder, KM <i>et al.</i> Abnormal neurotransmission in mice lacking synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci (USA). 1999; 96(26):15268-15273				
	LR	Feany, MB <i>et al.</i> The synaptic vesicle protein SV2 is a novel type of transmembrane transporter. Cell. 1992; 70(5):861-867				
	MR	Fuks, B, <i>et al.</i> Localization and photoaffinity labelling of the levetiracetam binding site in rat brain and certain cell lines. European Journal of Pharmacology 478 (2003) pp. 11-19				
	NR	Hayashi, M <i>et al.</i> Synaptic vesicle protein SV2B, but not SV2A, is predominantly expressed and associated with microvesicles in rat pinealocytes. Adv Exp Med Biol. 1999; 460:91-93				
	OR	Janz, R <i>et al.</i> SVOP, an evolutionarily conserved synaptic vesicle protein, suggests novel transport functions of synaptic vesicles. J Neurosci. 1998; 18(22):9269-9281				
	PR	Janz, R <i>et al.</i> SV2A and SV2B function as redundant Ca <sup>2+</sup> regulators in neurotransmitter release. Neuron. 1999; 24(4):1003-1016				
	QR	Janz, R. Knockout mice and SV2 synaptic-vesicle proteins. University of Texas Health Science Center at Houston Neuroscience Research Center Newsletter, 2001; 7(3):1,4-5				
CyW	RR	Lynch B, <i>et al.</i> The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. PNAS, June 29, 2004, vol. 101, no. 26, pp. 9861-9866				


Examiner

Date Considered:

2/8/06

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 (modified)		Attorney Docket No.	Client Ref.
To: U.S. Department of Commerce Patent and Trademark Office		053529-5007-01	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Applicant: Berkley LYNCH <i>et al.</i>	
		Appln. No.: 10/725,189	
		Filing Date: December 2, 2003	
		Examiner: Unassigned	Group Art Unit: 1711
Page 2 of 2			



U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						

FOREIGN PATENT DOCUMENTS					English Abstract		Translation Readily Available	
	Document Number	Date MM/YYYY	Country	Inventor Name	Enclosed	No	Enclosed	No
DR								
ER								
FR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)								
CyW	GR	Margineanu, DG <i>et al.</i> Levettiracetam: Mechanisms of action. In: Antiepileptic Drugs, 5th Edition. Levy, RH <i>et al.</i> eds. 2002; Lippincott Williams & Wilkins, Philadelphia, PA. Pp. 419-427						
	HR	Noyer, M <i>et al.</i> The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol. 1995; 286(2):137-146						
	IR	Pyle, RA <i>et al.</i> Phosphorylation of synaptic vesicle protein 2 modulates binding to synaptotagmin. J Biol Chem. 2000; 275(22):17195-17200						
	JR	Schivell, AE <i>et al.</i> Isoform-specific, calcium-regulated interaction of the synaptic vesicle proteins SV2 and synaptotagmin. J Biol Chem. 1996; 271(44):27770-27775						
	KR	Son, Y-J <i>et al.</i> The synaptic vesicle protein SV2 is complexed with an alpha5-containing laminin on the nerve terminal surface. J Biol Chem. 2000; 275(1):451-460						
	LR	Xu, T <i>et al.</i> SV2 modulates the size of the readily releasable pool of secretory vesicles. Nat Cell Biol. 2001; 3(8):691-698						
	MR	Nagase <i>et al.</i> , Prediction of the Coding Sequences of Unidentified Human Genes. XI. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins <i>in vitro</i> . DNA Research 5, 1998, 277-286						
CyW	NR	Genbank Accession 094841, May 1, 1999, KIAA0736 Human SV2						
	OR							

Examiner	<i>Changfu Jia</i>	Date Considered:	2/8/06
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.			